Literatura científica selecionada sobre o tema "Chaînes légères libres kappa"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "Chaînes légères libres kappa".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Artigos de revistas sobre o assunto "Chaînes légères libres kappa"
Micoud, Eléonore, Morgane Gossez, Françoise Poitevin, Christophe Malcus, Guillaume Monneret e Marine Godignon. "Apport du dosage des chaînes légères libres kappa et lambda dans le diagnostic de la sclérose en plaques". Revue Francophone des Laboratoires 2021, n.º 531 (abril de 2021): 58–64. http://dx.doi.org/10.1016/s1773-035x(21)00108-8.
Texto completo da fonteBertho, Pierre Olivier, Edouard Le Carpentier, Guillaume Herbreteau, Anne Hay-Lombardie e Edith Bigot-Corbel. "Dosage des chaînes légères libres Kappa dans le LCS et apport de l’index Kappa selon la présence ou non de bandes oligoclonales d’IgG". Revue Neurologique 177 (abril de 2021): S130. http://dx.doi.org/10.1016/j.neurol.2021.02.379.
Texto completo da fonteGuillermin, Y., A. S. Michallet, C. Lombard, C. Chapuis Cellier, Q. Reynaud, A. Chuilon, G. Salles, I. Durieu e J. C. Lega. "Le ration kappa/lambda des chaînes légères libres sériques est un biomarqueur prédictif de la rechute dans la thrombopénie auto-immune idiopathique". La Revue de Médecine Interne 36 (junho de 2015): A52. http://dx.doi.org/10.1016/j.revmed.2015.03.286.
Texto completo da fonteWang, Michael, Stefan Jevtic, Ryan Rebello e Adam Komorowski. "Lenalidomide-Associated Progressive Multifocal Leukoencephalopathy". Canadian Journal of General Internal Medicine 18, n.º 2 (5 de junho de 2023): 12–17. http://dx.doi.org/10.22374/cjgim.v18i2.687.
Texto completo da fonteMartellosio, J. P., A. Barra, F. Roy-Peaud, O. Souchaud-Debouverie, C. Lateur, J. M. Gombert, P. Roblot e M. Puyade. "Étude du comportement du rapport kappa/lambda des chaînes légères libres sériques (test Freelite) et du rapport Ig kappa/Ig lambda (test Hevylite) chez 32 patients adultes atteints de PTI (purpura thrombopénique immunologique)". La Revue de Médecine Interne 39 (dezembro de 2018): A152—A153. http://dx.doi.org/10.1016/j.revmed.2018.10.102.
Texto completo da fonteMartellosio, J. P., X. Leleu, P. Roblot, M. Martin e M. Puyade. "Dosage des chaînes légères libres : indications et méthodes". La Revue de Médecine Interne 40, n.º 5 (maio de 2019): 297–305. http://dx.doi.org/10.1016/j.revmed.2019.01.005.
Texto completo da fonteEmile, Carole. "Dosage des chaînes légères libres dans les gammapathies monoclonales". Option/Bio 25, n.º 508-509 (maio de 2014): 19–20. http://dx.doi.org/10.1016/s0992-5945(14)71773-8.
Texto completo da fonteChevailler, Alain, Bach-Nga Pham e Marie-Christine Bene. "Du bon usage des dosages des chaînes légères libres d'immunoglobulines". Revue Francophone des Laboratoires 2007, n.º 394 (julho de 2007): 21. http://dx.doi.org/10.1016/s1773-035x(07)80299-1.
Texto completo da fonteForay, V., e C. Chapuis-Cellier. "Apport du dosage des chaînes légères libres d'immunoglobulines dans le diagnostic et le suivi des gammapathies monoclonales à chaînes légères". Immuno-analyse & Biologie Spécialisée 20, n.º 6 (dezembro de 2005): 385–93. http://dx.doi.org/10.1016/j.immbio.2005.10.004.
Texto completo da fonteÉmile, Carole. "Apport du dosage des chaînes légères libres sériques en hématologie clinique". Option/Bio 23, n.º 470 (abril de 2012): 20–21. http://dx.doi.org/10.1016/s0992-5945(12)71239-4.
Texto completo da fonteTeses / dissertações sobre o assunto "Chaînes légères libres kappa"
Levraut, Michaël. "Évaluations des chaînes légères libres sériques et intrathécales comme biomarqueur diagnostique et pronostique dans la sclérose en plaques". Electronic Thesis or Diss., Université Côte d'Azur, 2023. http://www.theses.fr/2023COAZ6055.
Texto completo da fonteMultiple sclerosis (MS) is one of the most common central nervous system (CNS) inflammatory and demyelinating disease worldwide, and is the main cause of non-traumatic disability in young adults. Multiple sclerosis prognosis improved during the past 20-years because of treatments development and efficacy and the successive revisions of MS diagnostic criteria that allow to diagnose MS sooner, thanks to their high sensitivity. Nonetheless, the gain in sensitivity in MS diagnostic criteria leads to a loss of specificity increasing the risk of misdiagnosis. We lack sensitive and specific biomarkers that could help clinicians to diagnose MS accurately. Given the pathological processes leading to CNS inflammation in MS, we aimed to evaluate the diagnostic performances of four cytokines implicated in different inflammatory mechanisms (IL-1β, soluble IL-2 receptor (sIL-2R), IL-6, et IL-10) and kappa free light chains (kappa FLC). The performances of all these biomarkers were compared to those of oligoclonal bands (OCB).In Nice University Hospital MS tertiary center, we set up a monocentric prospective cohort (CyBIRD cohort, NCT05056740) that included all adult patients referred for a clinical or MRI suspicion of MS. Of the 176 included patients, both the kappa FLC index and the kappa FLC intrathecal fraction (IF) were able to differentiate MS and non-MS patients (AUC of 0.90 and 0.89 respectively). Cerebrospinal fluid (CSF) IL-6 and sIL-2R concentrations favored non-MS inflammatory CNS disorders (AUC of 0.87 and 0.77 respectively). According to our optimal threshold, a positive kappa FLC index performed better than OB for MS diagnosis (AUC 0.82 vs 0.74).To confirm our results, we conducted, on behalf of the French MS Society, a multicenter retrospective study where 1,621 patients were included. Based on this cohort, the kappa FLC index (AUC 0.94) and the kappa FLC IF (0.94) had similar diagnostic performances (p=.123), higher than the CSF kappa FLC concentration ones (AUC 0.91, p<.0001). A positive kappa FLC index (threshold of 8.9) was more sensitive (88% vs 82%) and as specific as OB (89% vs 90%). We also found that the kappa FLC index value was not influenced by baseline MS clinical characteristics, by samples or analyzers differences, nor by steroid exposure at sampling reinforcing its interest as diagnostic biomarker.Finally, we evaluated whether the baseline value of the kappa FLC index was able to predict clinical relapses or new MRI lesions during follow-up, in patients presenting with clinically or radiologically isolated syndromes (CIS and RIS). Based on the retrospective study of 182 patients (146 CIS and 36 RIS), the kappa FLC index was able to predict new MRI lesions in CIS (AUC of 0.86 and 0.96 at 12 and 48 months respectively - Hazard ratio of 1.06 [1.04; 1.07], p<.0001), and in RIS (AUC of 0.84 and 0.64 at 12 and 24 months respectively - Hazard ratio of 1.08 [1.03; 1.13], p=.002), but also clinical relapse in CIS (AUC of 0.75 and 0.87 at 12 and 48 months respectively - Hazard ratio of 1.04 [1.01; 1.07], p=.007).Our results suggest that a kappa FLC CSF-restricted synthesis (kappa FLC index or IF) is sensitive and specific for MS diagnosis, and may predict clinical and MRI disease course in the earliest phases of the disease. Therefore we suggest adding kappa FLC biomarkers (whether it is kappa FLC index or IF) in the further revisions of MS diagnostic criteria